Adaptive Biotechnologies Corp. (ADPT)
25.55
-0.44
(-1.69%)
USD |
NASDAQ |
Aug 24, 16:00
25.54
-0.01
(-0.04%)
After-Hours: 20:00
Adaptive Biotechnologies Debt to Equity Ratio : 2.872 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.872 |
| March 31, 2026 | 0.9623 |
| December 31, 2025 | 0.9614 |
| September 30, 2025 | 1.045 |
| June 30, 2025 | 1.213 |
| March 31, 2025 | 1.158 |
| December 31, 2024 | 1.098 |
| September 30, 2024 | 1.003 |
| June 30, 2024 | 0.9365 |
| March 31, 2024 | 0.8295 |
| December 31, 2023 | 0.7439 |
| September 30, 2023 | 0.6392 |
| June 30, 2023 | 0.585 |
| March 31, 2023 | 0.549 |
| December 31, 2022 | 0.5028 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.4789 |
| June 30, 2022 | 0.2148 |
| March 31, 2022 | 0.2052 |
| December 31, 2021 | 0.185 |
| September 30, 2021 | 0.1737 |
| June 30, 2021 | 0.1567 |
| March 31, 2021 | 0.1372 |
| December 31, 2020 | 0.1451 |
| September 30, 2020 | 0.0598 |
| June 30, 2020 | 0.0863 |
| March 31, 2020 | 0.069 |
| December 31, 2019 | 0.0641 |
| September 30, 2019 | 0.04 |
| June 30, 2019 | -1.976 |
| March 31, 2019 | -2.053 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Personalis, Inc. | 0.1616 |
| 10X Genomics, Inc. | 0.0954 |
| Alamar Biosciences, Inc. (California) | 0.1643 |
| Champions Oncology, Inc. | 1.167 |
| Medpace Holdings, Inc. | 0.3322 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 640.68M |
| Total Liabilities (Quarterly) | 490.02M |
| Shareholders Equity (Quarterly) | 142.91M |
| Current Ratio | 4.795 |
| Net Debt Paydown Yield | -1.11% |